Renal protection against ischaemia-reperfusion in transplantation | Not Recruiting
Renal protection against ischaemia-reperfusion in transplantation
Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Kidney transplantation
Primary Contact Details
Not Recruiting
Recruitment Status
Primary Trial ID Number
Not provided at time of registration
Research Details
  • Remote ischaemic preconditioning reduces ischaemia reperfusion injury to the kidney in living-donor transplantation and improves kidney function. Link to EME project website: Link to protocol: Please note that as of 04/08/10 this record has been updated to reflect changes to the exclusion criteria in the lastest protocol (v.7). Please see the revelant section for more details.
Sorry, this information is not available
Study Design
Double-blind factorial design randomised controlled trial
Study Type

The trial will test whether a simple procedure, the application of a blood pressure cuff to the arm of the donor and the recipient before a kidney transplant, can help protect the donor kidney from the harmful effects of the transplant. The blood pressure cuff to be used is similar to the one that is used to measure blood pressure. It will be inflated continuously for a five-minute period, after which it will be deflated for 5 minutes. This cycle of inflation, followed by deflation, will be performed 4 times in total. The trial follow up is 5 years, performed in the context of routine clinical follow up.

Intervention Type
Primary Outcome Measures
  • Glomerular filtration rate (GFR) 12 months after transplantation.
Secondary Outcome Measures
  • 1. Rate of fall in creatinine in the first 72 hours after transplantation
  • 2. Inflammatory response to surgery in the first 5 days after transplantation
  • 3. Protein expression in kidney parenchyma samples using histochemistry
  • 4. Protein activation and expression in renal vasculature using immunoblotting
  • 5. Kidney fibrosis 6 months after transplantation
  • 6. Alloreactivity of T-cells in the first 18 months after transplantation
  • 7. Patient outcomes 2 - 5 years after transplantation using renal registry data
2015 results in:
Result Reports
Sorry, this information is not available
Age Range
Who Can Participate
Number of Participants
Participant Inclusion Criteria
  • 1. Patients undergoing living donor transplantation
  • 2. Patients aged 18 years and above, either sex
Participant Exclusion Criteria
  • 1. 0,0,0-mismatched renal grafts (no mismatch in HLA-A/B/DR antigens between donor and recipient)
  • 2. Patients on adenosine triphosphate (ATP)-sensitive potassium channel opening or blocking drugs
  • 3. Patients on ciclosporin
  • 4. Patients who have had a previous transplant
  • 5. Patients with a known iodine sensitivity (who cannot undergo iohexol clearance studies)
  • Added 04/08/2010:
  • 6. Patients with ABO incompatability
  • 7. Any patient requiring HLA antibody removal therapy
Trial Location(s)
Trial Contact(s)
Primary Trial Contact
Prof Raymond MacAllister
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Netherlands, United Kingdom
Scientific Title
Renal protection against ischaemia-reperfusion in transplantation: a double-blind randomised controlled trial with a factorial design
EudraCT Number
Sorry, this information is not available
  • Medical Research Council (MRC)/National Institutes of Health Research (NIHR) (UK) - Efficacy and Mechanism Evaluation (EME) Programme (ref: EME 08/52/02)
Other Study ID Numbers
EME 08/52/02; 2 version 7
University College London (UCL) (UK)
Key Dates

Recruitment Start Date

01 Oct 2009

Recruitment End Date

01 Apr 2013

Trial Start Date

01 Oct 2009

Trial End Date

01 Apr 2013

Date Assigned

09 Jul 2009

Last Updated

29 May 2015